The role of oestrogen receptor α in human thyroid cancer: Contributions from coregulatory proteins and the tyrosine kinase receptor HER2

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages 255-264

  Kavanagh, Dara O ^a   McIlroy, Marie ^a,b   Myers, Eddie ^a   Bane, Fiona ^b   Crotty, Thomas B ^a   McDermott, E ^a   Hill, Arnold D ^a,b   Young, Leonie S ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 1;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CANCER; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CO-REPRESSOR PROTEINS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77449137742     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0216     Document Type: Article

References (33)

1. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, Hill AD & Young LS 2008 Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 27 3021-3031.
2. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B & Hynes NE 1988 Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Research 48 1238-1243.
3. Chen JD & Evans RM 1995 A transcriptional corepressor that interacts with nuclear hormone receptors. Nature 377 454-457.
4. Egawa C, Miyoshi Y, Iwao K, Shiba E & Noguchi S 2001 Quantitative analysis of estrogen receptor -alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 61 293-298.
5. Ensinger C, Prommegger R, Kendler D, Gabriel M, Spizzo G, Mikuz G & Kremser R 2003 Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Research 23 2349-2353.
6. Figge J 1999 Epidemiology of thyroid cancer. In Thyroid Cancer: a Comprehensive Guide to Clinical Management, pp 77-83. Ed L Wartofsky. Totowa: Humana Press.
7. Fleiss JL 1986 Introduction. In The Design and Analysis of Clinical Experiments. Ed. JL Fleiss. New York: John Wiley and Sons.
8. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill AD & Young LS 2004 Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. Journal of Clinical Pathology 57 1069-1074.
9. Goel A & Janknecht R 2004 Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. Journal of Biological Chemistry 279 14909-14916.
10. Goretski PE, Frilling A, Simon D & Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumours in man. Recent Results in Cancer Research 118 48-63.
11. Harvey JM, Clarke GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1482.
12. Jenster G & Spencer TE 1997 Steroid receptor induction of gene transcription: a two-step model. PNAS 94 7879-7884.
13. Kishino T, Watanabe M, Kimura M & Sugawara I 1997 Anti-proliferative effect of toremifene and tamoxifen on estrogen receptor-lacking anaplastic thyroid carcinoma cell lines. Biological & Pharmaceutical Bulletin 20 1257-1260.
14. Lee SH, Kim KM, Jung BH, Chung WY, Cheong SP & Chung BC 2003 Estrogens in female thyroid cancer: alteration of urinary profiles in pre- and post-operative cases. Cancer Letters 189 27-32.
15. Manole D, Schildknecht B, Gosnell B, Adams E & Derwahl M 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. Journal of Clinical Endocrinology and Metabolism 86 1072-1077.
16. McIlroy M, Fleming FJ, Buggy Y, Hill AD & Young LS 2006 Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer: a possible mechanism for ER isoform specific recurrence. Endocrine-Related Cancer 13 1135-1145.
17. Mondi MM, Rich R, Ituarte P, Wong M, Bergman S, Clark OH & Perrier ND 2003 HER2 expression in thyroid tumors. American Surgeon 69 1100-1103.
18. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S & Matsubara O 2005 Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for anew therapeutic approach. Pathology International 55 757-765.
19. Myers E, Fleming FJ, Crotty T, Kelly G, McDermott EW, O'Higgins NJ, Hill AD & Young LS 2004 Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. British Journal of Cancer 91 1687-1693.
20. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y & Young LS 2005 Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clinical Cancer Research 11 2111-2122.
21. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
22. Osborne CK, Shou J, Massarweh S & Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11 865s-870s.
23. Qin L, Liu Z, Chen H & Xu J 2009 The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Research 69 3819-3827.
24. Redmond AM, Bane F, Stafford AT, Crotty TB, McIlroy M, Hill AD & Young LS 2009 Coassociation of ER and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clinical Cancer Research 15 2098-2106.
25. Rossing MA, Voigt LF, Wicklund KG & Daling JR 2000 Reproductive factors and risk of papillary thyroid cancer in women. American Journal of Epidemiology 151 765-772.
26. Sherman S 2003 Thyroid carcinoma. Lancet 361 501-512.
27. Smith CL & O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45-71.
28. Teppo L, Hakulinen T & Eurocare Working Group 1998 Variation in survival of adults with thyroid cancer in Europe. European Journal of Cancer 34 2248-2252.
29. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Ando S & Maggiolini M 2006 17Beta-estradiol, genistein and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPCR30. Molecular Pharmacology 70 1414-1423.
30. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O'Malley BW & Xu J 2009 Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis. PNAS 106 151-156.
31. Wiseman SM, Griffith OL, Melck A, Masoudi H, Gown A, Nabi IR & Jones SJ 2008 Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. American Journal of Surgery 195 667-673.
32. Xu J & Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular Endocrinology 17 1681-1692.
33. Zeng Q, Chen GG, Vlantis AC, Tse GM & van Hasselt CA 2008 The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. Journal of Pathology 214 425-433.